
浏览全部资源
扫码关注微信
纸质出版日期:2014
移动端阅览
程明霞, 李海燕, 齐尚书. 注射用血塞通对急性脑梗死血栓形成的影响[J]. 中国实验方剂学杂志, 2014,20(10):196-200.
CHENG Ming-xia, LI Hai-yan, QI Shang-shu. Influence of Xuesaitong Injection to Forming of Acute Cerebral Infarction[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(10): 196-200.
程明霞, 李海燕, 齐尚书. 注射用血塞通对急性脑梗死血栓形成的影响[J]. 中国实验方剂学杂志, 2014,20(10):196-200. DOI: 10.13422/j.cnki.syfjx.2014100196.
CHENG Ming-xia, LI Hai-yan, QI Shang-shu. Influence of Xuesaitong Injection to Forming of Acute Cerebral Infarction[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(10): 196-200. DOI: 10.13422/j.cnki.syfjx.2014100196.
目的:探讨注射用血塞通对急性脑梗死的疗效和对血栓形成的影响及作用机制。方法:将63例急性期脑梗死患者随机按入院顺序分为对照组30例和观察组33例。两组均参照“中国急性缺血性脑卒中诊治指南2010”给予相应的内科治疗处理。抗凝采用拜阿司匹林肠溶片,100 mg/次,1次/d,晚饭后服用。观察组在对照组治疗的基础上加用注射用血塞通,0.4 g/次,静脉滴注,1次/d。两组疗程均为14 d。采用美国国立卫生研究院卒中量表(NIHSS)量表评估神经功能 缺损严重程度,分别于第7,14天评价;检测治疗前后抗凝酶Ⅲ(ATⅢ)、纤维蛋白原(FIB)、定D-二聚体(D-D)、血小板计数,血小板体积分布宽度(PDW)、平均血小板体积(MPV)、大型血小板比率(P-LCR)、血小板聚集率(MPAR)、血栓素B2(TXB2)及6-酮-腺素F_la(6-Keto-PGF_la)变化。结果:经Ridit分析,观察组临床疗效优于对照组(P<0.05);治疗后7 d,两组NIHSS评分均比治疗前下降(P<0.01);治疗后14 d,两组NIHSS评分继续下降(P<0.01),观察组NIHSS评分低于对照组(P<0.01);治疗后观察组FIB,D-D及MPAR均低于对照组(P<0.01),ATⅢ高于对照组(P<0.01);观察组治疗后PDW,MPV较治疗前减小,P-LCR较治疗前减少,与治疗后对照组比较,差异也有统计学意义(P<0.05或P<0.01);治疗后观察组TXB2水平低于对照组,6-Keto-PGF_la水平高于对照组(P<0.01)。结论:注射用血塞通可通过多途径的抗血小板聚集、抑制血栓形成作用,改善急性脑梗死患者梗死区及其周围半暗带的血液供应,促进神经功能的恢复。
Objective: Discussing curative effect of Xuesaitong injection on acute cerebral
the influence to thrombosis and mechanism of action. Method: Sixty three cases with acute cerebral infarction randomly divided into control group (30 cases) and observation group (33 cases).Both groups' patients received medical treatment refer to 'Chinese Cerebral Ischemic Stroke Treatment Guidelines in 2010'.Anticoagulant use worship aspirin enteric-coated tablets
100 mg/time
1 time/day
taken orally after dinner.Based on treatment of the control group
patients in the observation group added Xuesaitong injection
0.4 g/time
intravenous drip
1 time/day.Course of treatment in two groups was 14 days. Severity degree of neurologic impairment by national institutes of health stroke scale (NIHSS). In 7
the 14 day evaluation
detecting the change of antithrombase (ATⅢ)
fibrinogen(FIB)
given D-dimer(D-D)
blood platelet count
platelet volume distribution width (PDW)
mean platelet volume (MPV)
large platelet ratio (P-LCR)
platelet aggregation rate (MPAR)
thromboxance B2(TXB2) and 6-keto-prostaglandin F_la (6-Keto-PGF_la) before and after treatment. Result: Analyzed by ridit
clinical curative effect in the observation group was superior to the control group(P<0.05).At the seventh day after treatment
NIHSS scores in the two groups decreased(P<0.01).At the fourteenth day after treatment
NIHSS scores in the two groups sequentially decreased(P<0.01)
and NIHSS score in the observation group was lower than the control group(P<0.01).After treatment
FIB
D-D and MPAR in the observation group were all lower than the control group(P<0.01)
ATⅢ was higher than the control group(P<0.01).Compared with the time before treatment
PDW
MPV and P-LCR in the observation group reduced
and compared with the control group after treatment
which also meant a statistical significance from the differences between two groups(P<0.05 or P<0.01).The level of TXB2 in the observation group was lower than the control group
and 6-Keto-PGF_la was higher than the control group(P<0.01). Conclusion: Xuesaitong injection can antiplatelet aggregative
restrain forming thrombosis by several routes
ameliorated acute cerebral infarction region and blood supplying of penumbra around
and improve the recovery of nerve function.
0
浏览量
6
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621